1. What Is the Companion Diagnostic Market?
The Companion Diagnostic Market covers in-vitro diagnostic tests identifying patients most likely to benefit from a specific therapeutic, required by regulatory agencies as part of the drug approval label. Companion diagnostics encompasses FDA-required IVD tests for NSCLC, breast cancer, melanoma, and haematological cancer targeted therapy prescribing decisions. Market dynamics reflect oncology precision medicine driving companion diagnostic co-development, FDA breakthrough device designation expediting approval, and liquid biopsy companion diagnostic development enabling blood-based tumour marker testing.
2. Companion Diagnostic Market Size & Forecast
3. Emerging Technologies
- Tumour-agnostic companion diagnostics identifying biomarkers like NTRK fusion, RET, and TMB across multiple cancer types are advancing as multi-indication approval tools. Growing adoption at pharma companies is driven by tissue-agnostic targeted therapy co-development requirements.
- AI digital pathology companion diagnostics predicting therapy response from H&E stained slides without biomarker-specific staining are advancing. Growing adoption at pathology labs is driven by biomarker test standardisation and access requirements.
- Multi-cancer early detection companion diagnostics identifying minimal residual disease from blood ctDNA are advancing as monitoring tools. Growing adoption at oncology clinics is driven by therapy response monitoring requirements.
- Real-world data companion diagnostic validation studies demonstrating companion diagnostic effectiveness outside clinical trial settings are advancing. Growing adoption at payer coverage evaluation is driven by real-world evidence requirements.
Similar technologies are also transforming adjacent markets. Learn more in our Hereditary Cancer Testing Market.
4. Key Market Opportunity
The primary growth driver in the Companion Diagnostic Market is the NGS comprehensive panel sub-market, where FoundationOne CDx and Tempus xT achieve multi-indication companion diagnostic approvals enabling a single test to inform multiple therapy decisions. Liquid biopsy companion diagnostics create an access expansion opportunity as blood-based testing reaches patients unable to undergo surgical biopsy. Tumour-agnostic companion diagnostics creates a high-value regulatory opportunity as FDA tumour-agnostic approvals enable companion diagnostics across multiple cancer types. Asia Pacific companion diagnostics creates geographic expansion as Japanese and Chinese precision oncology programme investment drives regional companion diagnostic adoption.
5. Top Companies in the Companion Diagnostic Market
The following organisations hold leading positions in the Companion Diagnostic Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Foundation Medicine (Roche)
- Guardant Health
- Qiagen
- Agilent Technologies
- Thermo Fisher (Ion Torrent)
- Illumina
- Myriad Genetics
- Tempus AI
- NeoGenomics
- Veracyte
6. Market Segmentation
The Companion Diagnostic Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Platform | IHC ImmunohistochemistryFISHNext-Gen SequencingPCRLiquid Biopsy |
| By Indication | NSCLCBreast CancerMelanomaColorectalHaematological |
| By Partner | Pharma Co-DevelopmentIVD Manufacturer |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Companion Diagnostic Market trajectory over the forecast period:
FDA Approves 45 Companion Diagnostics in 2024 Establishing Record Annual Approval Rate.FDA total approved companion diagnostic test count reaching 110 by end 2024 with 45 new approvals demonstrates the acceleration of precision medicine biomarker test approvals. Roche VENTANA PD-L1 and Foundation Medicine FoundationOne CDx approvals for additional therapy indications demonstrate the extension of companion diagnostic utility across multiple targeted therapy biomarkers.
Foundation Medicine FoundationOne CDx Achieves Status as Broadest Panel Companion Diagnostic Covering 324 Genes.Foundation Medicine FoundationOne CDx achieving FDA approval as companion diagnostic for 30-plus targeted therapies across 9 solid tumour types demonstrates the comprehensive tissue-based NGS companion diagnostic platform. FoundationOne CDx revenue reaching USD 700 million in 2024 demonstrates companion diagnostic NGS panel commercial viability at oncology scale.
Guardant Health Guardant360 CDx Achieves FDA Approval as Liquid Biopsy Companion Diagnostic.Guardant360 CDx achieving FDA companion diagnostic approval for NSCLC EGFR, ALK, RET, and PIK3CA biomarker identification from blood plasma demonstrates liquid biopsy companion diagnostic entering mainstream oncology prescribing. Guardant360 CDx enabling companion diagnostic testing without surgical tissue biopsy demonstrates the patient access advantage of liquid biopsy.
For related market intelligence, see the Car T Cell Therapy Market.
8. Segmental Analysis
By platform, the NGS advanced Sequencing segment dominated the Companion Diagnostic Market in 2025. Representing the largest revenue category as FoundationOne CDx and Tempus xT achieve comprehensive panel companion diagnostic approval. The Liquid Biopsy segment is the fastest-growing category, advancing as blood-based CDx enables companion diagnostic testing without surgical biopsy at scale.
By indication, the NSCLC segment dominated the Companion Diagnostic Market in 2025. Representing the largest indication revenue share. The Breast Cancer and Colorectal segment is the fastest-growing indication category, advancing as s. The NSCLC structural position and Breast Cancer and Colorectal growth momentum establish the core indication segmentation dynamic for the Companion Diagnostic Market through 2034.
By partner, Pharma Co-Development dominated the Companion Diagnostic Market in 2025, as integrated drug-diagnostic approval pathways require biopharmaceutical sponsors to lead CDx development programmes. The IVD Manufacturer category is the fastest-growing partner model, driven by diagnostic companies developing multi-target panel CDx for expanding precision medicine therapy portfolios.
9. Regional Analysis
Regional demand patterns across the Companion Diagnostic Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Companion Diagnostic Market in 2025, holding 50.7% of the global market. Pharmaceutical companies, oncology diagnostic laboratories, and clinical genomics organisations are deploying companion diagnostic platforms to identify patient biomarkers determining therapeutic eligibility for targeted cancer therapies and immunotherapy treatments. FDA companion diagnostic co-development requirements and growing pharmaceutical investment in precision oncology drug programmes requiring companion diagnostic approval are encouraging diagnostic company investment. High pharmaceutical R&D spending, established regulatory companion diagnostic frameworks, and large oncology patient populations are generating strong regional companion diagnostic demand.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 17.78% during the forecast period. Pharmaceutical companies and clinical diagnostic organisations across China, Japan, South Korea, and India are deploying companion diagnostic platforms to drives growing targeted therapy pipelines and personalised medicine programmes in oncology. Government precision medicine investment programmes and increasing regulatory requirements for biomarker-guided therapy prescribing in oncology are encouraging companion diagnostic development and adoption. Rising pharmaceutical investment in targeted oncology therapies requiring companion diagnostics and growing clinical adoption of biomarker-guided treatment decisions are generating demand.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Companion Diagnostic Market was valued at USD 8.48 Bn in 2025 and is projected to reach USD 28.90 Bn by 2034, growing at a CAGR of 14.6% over the 2026–2034 forecast period.
The Companion Diagnostic Market is projected to grow at a CAGR of 14.6% from 2026 to 2034.
North America accounted for the largest share of the Companion Diagnostic Market in 2025, holding 50.7% of the global market.
The leading companies in the Companion Diagnostic Market include Foundation Medicine (Roche), Guardant Health, Qiagen, Agilent Technologies, Thermo Fisher (Ion Torrent), Illumina, Myriad Genetics, Tempus AI, NeoGenomics, Veracyte.
Fda approves 45 companion diagnostics in 2024 establishing record annual approval rate.
By platform, the NGS advanced Sequencing segment dominated the Companion Diagnostic Market in 2025.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.